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a  b  s  t  r  a  c  t
PAX5  rearrangements  resulting  in  the  expression  of  fusion  transcripts  account  for 2–3%  of childhood  B-
cell precursor  acute  lymphoblastic  leukemia.  Most  PAX5  fusions  are  rare  and  many  of  them  have  only
been  described  in a couple  of, or even  only  in  single,  cases.  We  have  identiﬁed  the  third  case  with  accepted 16 April 2012
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PAX5-AUTS2  fusion,  which  results  from  unbalanced  t(7;9)(q11.2;p13.2)  rearrangements.  Our  ﬁndings
substantiate  that  PAX5-AUTS2  is  a  recurrent  fusion  gene  in pediatric  B-cell  precursor  acute  lymphoblastic
leukemia,  and  we  summarize  the  clinical  characteristics  of  such  patients.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. hildhood acute lymphoblastic leukemia
. Introduction
In pediatric B-cell precursor acute lymphoblastic leukemia
BCP-ALL) PAX5 is one of the most frequent targets affected by
enetic alterations including deletions, point mutations, and gene
earrangements [1]. PAX5 deletions and PAX5 mutations are found
n about 30% and 5–7% of the cases, respectively, and PAX5 rear-
angements in 2–3% [1–4]. PAX5 rearrangements either result
n bona ﬁde in-frame fusions and the expression of chimeric
ranscripts [1,3,4] or in PAX5 fusions to genes in opposite orienta-
ion, out-of-frame fusions or the expression of truncated isoforms
4].
To date, 16 different in-frame PAX5 fusion partners comprising
 heterogeneous group of genes that encode transcription factors,
tructural proteins, the non-receptor tyrosine kinase JAK2, and sev-
ral with so far unknown functions have been reported [1,3,4].  A
nifying feature of all PAX5 fusion proteins is the retention of the
AX5 paired DNA-binding domain (PD), which is fused to either the
ntire fusion partner protein or its C-terminal portion [1,3,4].
While many of the PAX5 fusions have so far only been observed
n a couple of, or only single, cases, a number of them are more
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Open access under CC BY-NC-ND license. commonly found. The most frequently observed rearrangements
are PAX5-ETV6 and PAX5-C20orf112 followed by PAX5-ELN,  PAX5-
FOXP1,  and PAX5-JAK2 each of which has been detected in at least
three cases [1,3–5].
We  here report the third case with a PAX5-AUTS2 fusion
resulting from unbalanced t(7;9)(q11.2;p13.2) rearrangements and
summarize the clinical and laboratory characteristics of these
patients.
2. Patient and methods
2.1. Case report
A 7-month-old boy presented with 158 ×109/L leucocytes in the peripheral
blood (PB) and 91% and 89% blast cell inﬁltration in the PB and bone marrow (BM),
respectively (Table 1). The blast cells showed an L1 morphology and immunophe-
notyping established the diagnosis of a CD10+ BCP-ALL. Ninety percent of the blast
cells were CD19 and CD10 positive and ∼10% weakly positive for cytoplasmic IgM;
and they were negative for the myeloid markers CD13, CD15, CD33, and MPO and
the  T-cell markers cytoplasmic CD3 and surface CD7.
Because of a poor prednisone response at day 8 the patient was treated, with
informed consent, in the high risk group (HRG) of the ALL-BFM 90 clinical trial.
A  complete morphologic remission (CR) was achieved after completion of induc-
tion therapy; however, 2.1 years after initial diagnosis the patient had a central
nervous system (CNS) relapse. The patient achieved a second CR but died of an infec-
tious complication 3.4 years after initial diagnosis. Cytogenetics of the PB showed a
46,XY,t(7;9)(q11;p13) karyotype, and ﬂuorescence in situ hybridization (FISH) indi-
cated a PAX5 rearrangement. The patient’s laboratory and clinical parameters are
summarized in Tables 1 and 2.
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Table 1
Patient and laboratory data of PAX5-AUTS2 positive cases.
No. Age (yrs) Sex WBC  (×109/L) Blasts BM Morphology/phenotype Karyotype Reference
1 3.1 M 171.5 93% L1/B-III 45,XY,-7,der(9)t(7;9)(q11;p13)[15]/46,XY[1] Kawamata et al.a [6]
2  2.8 F 5.6 80% L1/B-III 45,XX,-
7,der(9)t(7;9)(q11;p13),dup(16)(p11p13)[14]/
46,XX[2]
Coyaud et al. [7]
3 0.6  M 158.0 89% L1/B-II/III 46,XY,t(7;9)(q11;p13)[8] This work
BM,  bone marrow; WBC, white blood cell count; yrs, years.
a Initially in this case no cytogenetic analysis was  performed.
Table 2
Clinical characteristics and outcome of PAX5-AUTS2 positive cases.
No. Clinical trial CNS disease MRD day 33 MRD day 78 MRD risk Prednisone response CR day 33 Risk group Relapse Time to relapse
(yrs)a
Outcome Follow-up (yrs)b
1 ALL-BFM 2000 Yes 10−4 Neg IR Good Yes MRG  1st BM
2nd BM
1.4
1.6
Dead 1.7
2 ALL-BFM 2000 No Neg Neg LR Good Yes SRG / / 1st CR 2.2+
3 ALL-BFM 90c No ND ND ND Poor Yes HRG CNS 2.1 Dead 3.4
BM,  bone marrow; CNS, central nervous system; CR, complete morphologic remission; MRD, minimal residual disease; ND, not determined; IR, intermediate risk; LR, low risk; MRG, medium risk group; SRG, standard risk group;
HRG,  high risk group; yrs, years.
a From initial diagnosis.
b Follow-up from initial diagnosis to date of death or last follow-up date.
c In the ALL-BFM 90 trial MRD  was  not used as parameter for risk stratiﬁcation.
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Fig. 1. Molecular genetic analysis of PAX5-AUTS2 positive case. (A) FISH using PAX5-spe
end-speciﬁc clone (red signals). (B) RT-PCR using primers located in PAX5 exon 5 and AUT
weight marker 100 bp ladder (Promega); lane 1, patient No. 3; lane 2, normal control; la
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ounction showing fusion between exon 6 of PAX5 and exon 6 of AUTS2.  (D) Schema
s  well as the putative consensus chimeric protein (middle). PD, paired domain; O
istidine-rich regions; P, proline-rich region; arrows indicate nuclear localization s
.2.  FISH and Reverse Transcription-Polymerase Chain Reaction
FISH using PAX5-speciﬁc cosmid probes was  conducted as described [3].
T-PCR for the detection of PAX5-AUTS2 transcripts was performed using
rimers PAX5ex5-F1 (5′-TACTCCATCAGCGGCATCC-3′) and AUTS2ex8-R1 (5′-
ATTGGCTGTGCGACCTGAG-3′) located in exons 5 and 8 of PAX5 and AUTS2,
espectively; the ampliﬁcation product was directly sequenced (Euroﬁns, MWG,
peron, Germany). The exon nomenclature used corresponds to that of the NCBI
eference sequences PAX5 NM 016734.1 and AUTS2 NM 015570.2 (accessed March
012).
.3.  In silico protein analysis
Protein analysis was  performed using BLASTP and COBALT (http://www.
cbi.nlm.nih.gov), PSORTII (http://psort.hgc.jp) and CAST (http://athina.biol.
oa.gr/CAST/). Further information regarding the AUTS2 protein family and
osttranslational modiﬁcations were obtained from PRINTS (http://www.
ioinf.man.ac.uk/)  and the PhosphoSitePlus® database (http://www.phosphosite.
rg).
. Results and discussionInterphase FISH of a pediatric BCP-ALL with a t(7;9)(q11;p13)
sing PAX5-speciﬁc probes detected a 3′-end deletion of the gene
Fig. 1A) suggesting the presence of a PAX5 fusion with a partner
ene located at 7q11. Subsequent RT-PCR revealed the expression
f PAX5-AUTS2 transcripts, in which exon 6 of PAX5 was  fused toch 36 (2012) e178– e181
ciﬁc cosmids showing a 3′-end deletion: 5′-end-speciﬁc clone (green signals); 3′-
S2 exon 8 resulting in ampliﬁcation of PAX5-AUTS2 fusion transcripts. M,  molecular
ne 3, no template control. (C) Sequence chromatogram of the PAX5-AUTS2 fusion
resentation of the structure of PAX5 (top) and AUTS2 (bottom) wild-type proteins
peptide; HD, homeodomain; TA, transactivation domain; I, inhibitory domain; H,
NLS); ﬁlled lollipops represent serine phosphorylation sites.
exon 6 of AUTS2 (Fig. 1B and C). Similar in-frame fusions of PAX5
exon 6 to AUTS2 exons 4 or 7 have been previously described [6,7].
Therefore, the breakpoints within AUTS2 appear to be variable but
that within PAX5 consistently occurs in intron 6.
Since PAX5 and AUTS2 are transcribed in the same – centromere
to telomere – orientation, a reciprocal translocation may  generate
the fusion gene. However, in two cases due to loss of the der(7)
chromosome the translocation was unbalanced (Table 1). This is
also reﬂected by the detection of one of the cases by SNP arrays (No.
1; Table 1), which can only indicate fusion genes in case of unbal-
anced rearrangements [6].  Karyotyping of this previously published
case now conﬁrmed loss of the der(7). The cytogenetically unbal-
anced translocations in two  of the PAX5-AUTS2 cases and loss of the
PAX5 3′-end in the third one underline the observation that in the
majority of PAX5-rearranged cases the reciprocal fusion transcripts
are not expressed [3,4] and that, thus, the PAX5-partner fusions
drive leukemogenesis [1].
The putative consensus chimeric protein deduced from the
fusion transcripts not only contains the PAX5 PD, which is typically
retained in all PAX5 fusion proteins [1,3,4],  but also the octapeptide
motif, the nuclear localization signal (NLS), and the homeodomain,
which are fused to the C-terminal regions of AUTS2 (Fig. 1D). With
the exception of PAX5-ETV6, in which only the PAX5 PD is main-
tained, in several PAX5 fusions the breakpoint occurs in intron
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, therefore, also the NLS is present [1,4]. In the remaining PAX5
usions the breakpoints are located within further downstream
ntrons resulting in the retention of additional conserved protein
omains [1,4]. Thus, PAX5-AUTS2 may  belong to a subtype of PAX5
usion proteins whose function might be distinct from those that
etain only the PD.
AUTS2, which is expressed in the developing brain, has been
escribed as autism susceptibility candidate gene 2 and its
utation has also been linked to autosomal dominant mental retar-
ation [8].  The nuclear protein AUTS2 belongs to the ﬁbrosin-1-like
rotein family, which consists of AUTS2, FBRS (ﬁbrosin), and FBRSL1
ﬁbrosin-like 1), which share a so-called FIBROSIN1LPF 5-element
ngerprint signature. Moreover, AUTS2 is highly conserved among
pecies and harbors several putative NLSs, two proline- alternating
ith two histidine-rich regions, and two potential serine phos-
horylation sites (Fig. 1D); the function of the latter sites has,
owever, not been analyzed in detail yet. In the putative PAX5-
UTS2 chimeric protein almost the entire AUTS2 protein, except
or the region containing the NLSs, is fused to PAX5 which retains
ts NLS (Fig. 1D).
Regarding the clinical course, all three PAX5-AUTS2 positive
atients were assigned to different risk arms of the respective clin-
cal trials. They all achieved a CR after completion of induction
herapy; however, two of the patients experienced an early relapse
nd both patients died, one from an infectious complication in sec-
nd CR and one from progressive leukemia after a further relapse.
he third patient remains in ﬁrst CR for more than two  years after
iagnosis (Table 2).
The general rarity of recurrent PAX5 fusion gene positive BCP-
LL precludes any conclusions regarding their prognostic value.
et, although the number of patients is very small, it is interesting to
ote that two of the three PAX5-AUTS2 patients had a CNS involve-
ent either at the time of diagnosis or relapse and two patients
xperienced early relapses tentatively indicating that PAX5-AUTS2
ositive cases may  have a rather poor outcome.In summary, the description of now three cases with a PAX5-
UTS2 fusion conﬁrms its recurrence in pediatric BCP-ALL and
mphasizes the importance of functional studies of PAX5 fusion
enes to understand the pathogenesis of this rare disease.
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